Format

Send to

Choose Destination
Oncotarget. 2017 Jun 16;8(38):62976-62983. doi: 10.18632/oncotarget.18520. eCollection 2017 Sep 8.

Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma.

Author information

1
Children's Cancer Therapy Development Institute, Beaverton, OR 97005, USA.
2
The Jackson Laboratory, Sacramento, CA 95838, USA.
3
Department of Orthopedics and Rehabilitation, Oregon Health & Science University, Portland, OR 97239, USA.
4
Genetics Branch, Oncogenomics Section, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA.
5
Pediatric Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA.
6
Department of Pathology, Oregon Health & Science University, Portland, OR 97239, USA.
7
Omics Data Automation, Beaverton, OR 97005, USA.
8
Molecular Pathology, Cancer Center, and Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
9
Harvard Stem Cell Institute, Cambridge, MA 02129, USA.

Abstract

Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. RMS often arise from myogenic precursors and displays a poorly differentiated skeletal muscle phenotype most closely resembling regenerating muscle. GSK3β is a ubiquitously expressed serine-threonine kinase capable of repressing the terminal myogenic differentiation program in cardiac and skeletal muscle. Recent unbiased chemical screening efforts have prioritized GSK3β inhibitors as inducers of myodifferentiation in RMS, suggesting efficacy as single agents in suppressing growth and promoting self-renewal in zebrafish transgenic embryonal RMS (eRMS) models in vivo. In this study, we tested the irreversible GSK3β-inhibitor, tideglusib for in vivo efficacy in patient-derived xenograft models of both alveolar rhabdomyosarcoma (aRMS) and eRMS. Tideglusib had effective on-target pharmacodynamic efficacy, but as a single agent had no effect on tumor progression or myodifferentiation. These results suggest that as monotherapy, GSK3β inhibitors may not be a viable treatment for aRMS or eRMS.

KEYWORDS:

GSK3β; myodifferentiation; patient-derived xenograft; preclinical testing; rhabdomyosarcoma

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center